Copyright Nasdaq. Minimum 15 minutes delayed.

A Clear Path Ahead

Immunovaccine (TSX: IMV) (TSX: IMV; OTCQX: IMMVF) has the potential to fundamentally transform the way we use our immune system to address a broad range of serious diseases. We continue to build value in our Company by establishing collaborations with leading biotechnology and pharmaceutical companies; advancing our programs; and seeking  additional opportunities to leverage DepoVax™ in underserved markets.

We have the platform, the pipeline, and the people and partners to discover and develop novel solutions to some of healthcare’s most vexing challenges. Through our internal development activities and external collaborations, we are growing a pipeline of promising combination immunotherapies and vaccines. Our experienced management team, Board of Directors, and scientific advisors are well prepared and committed to ensure that we deliver optimal value to patients and our shareholders, across all facets of our organization.

News Releases